NASDAQ: SIGASiga Technologies Inc Stock
$8.64-0.02 (-0.23%)
Updated Apr 25, 2024
SIGA Price
$8.64
Fair Value Price
$22.29
Market Cap
$614.23M
52 Week Low
$4.22
52 Week High
$10.00
P/E
9.09x
P/B
3.12x
P/S
2.86x
PEG
N/A
Dividend Yield
12.15%
Revenue
$139.92M
Earnings
$68.07M
Gross Margin
87.3%
Operating Margin
62.73%
Profit Margin
48.6%
Debt to Equity
0.29
Operating Cash Flow
$95M
Beta
0.81
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SIGA Overview
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SIGA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SIGA ($8.64) is undervalued by 61.23% relative to our estimate of its Fair Value price of $22.29 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SIGA ($8.64) is significantly undervalued by 61.23% relative to our estimate of its Fair Value price of $22.29 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SIGA is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more SIGA due diligence checks available for Premium users.
Be the first to know about important SIGA news, forecast changes, insider trades & much more!
SIGA News
Valuation
SIGA fair value
Fair Value of SIGA stock based on Discounted Cash Flow (DCF)
Price
$8.64
Fair Value
$22.29
Undervalued by
61.23%
SIGA ($8.64) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SIGA ($8.64) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SIGA is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SIGA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
9.09x
Industry
33.56x
Market
40.97x
SIGA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SIGA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SIGA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.12x
Industry
2.07x
SIGA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SIGA's financial health
Profit margin
Revenue
$116.5M
Net Income
$72.3M
Profit Margin
62%
SIGA's Earnings (EBIT) of $87.78M... subscribe to Premium to read more.
Interest Coverage Financials
SIGA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$254.4M
Liabilities
$57.5M
Debt to equity
0.29
SIGA's short-term assets ($238.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SIGA's short-term assets ($238.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SIGA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SIGA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$79.0M
Investing
$0.0
Financing
$0.0
SIGA's operating cash flow ($94.80M)... subscribe to Premium to read more.
Debt Coverage Financials
SIGA vs Pharmaceutical Stocks
Siga Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.